JBIO
Jade Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.94
−1.17%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$17.15
From 52W high−36.91%
Volume2.93M
Market cap$1.08B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$17.15
From 52W high
−36.91%
Volume
2.93M
Market cap
$1.08B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
P/E (TTM)
—
RSI (14)
30.6
MomentumView details →
1D Return
−1.17%
YTD Return
+9.07%
SummaryUpdated Jun 1, 2026
Jade Biosciences, Inc. (NASDAQ:JBIO) is a clinical-stage biotechnology company founded to develop innovative therapies for autoimmune diseases. The company went public in April 2025 and is headquartered in the United States. Jade Biosciences focuses specifically on addressing critical unmet medical needs in autoimmune conditions, with its lead program targeting a rare kidney disease called IgA nephropathy.
Similar companies
Latest newsMore news →
Jade Biosciences reported its financial results for the second quarter ending June 30, 2026, with cash, cash equivalents, and investments of $461 million as of that date, expected to provide runway into the fourth quarter of 2028.41d agoJade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share, expecting gross proceeds of $150.0 million.108d agoJade Biosciences announced interim results from a Phase 1 healthy volunteer study of JADE101, showing rapid and durable reductions in serum IgA, supporting advancement into patient studies for IgA nephropathy.110d ago